Atrius Health Urgent Care: Xylazine and Opiate Use Disorder, Enduring Version 12/6/23

Educational Needs Addressed
In this meeting, Atrius Health Urgent Care providers will learn about the most current Urgent Care practices, standards and guidelines to identify the signs and effects of xylazine use and how to monitor these patients. 

Target Audience

Atrius Health Clinicians

Learning Objectives

At the completion of this activity, pharmacists will be able to:

  • Understand the signs and effects of opioid use disorder, sexually transmitted disease and other frequently presented urgent care visits.
  • Describe the updated guidelines for presented topics.

  • Access resources and/or where to direct questions and referrals to continue best care.

Course summary
Available credit: 
  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 0.50 MA Opioid Education Statement
  • 0.50 ANCC
    • 0.50 ANCC Pharmacology
  • 0.50 Participation
Course opens: 
04/10/2024
Course expires: 
10/10/2024
Rating: 
0

Faculty Presenters and Disclosures
David McGinnis, MD
Course Director and Speaker 
Urgent Care
Harvard Vanguard Medical Associates

Dr. Mcginnis does not have any relevant financial relationships to disclose. 

Off-Label Discussion
The faculty members do not plan on discussing the unlabeled/investigational use of any commercial products. 

Planning Committee and Disclosures
Mark Boardman, PA; Randi Rose, NP and Emily Arthur have no relevant financial relationships to disclose.

Accreditor Disclosures
The following planning committee members from Boston University Chobanian & Avedisian School of Medicine’s Office of Continuing Medical Education have no relevant financial relationships with ineligible companies:
Michael Burk, BS – Operations Manager

Accreditor Disclosure Policy
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.

Disclaimer
THIS CONTINUING  EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.  NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

 

 

 

 

In support of improving patient care, this activity has been planned and implemented by Boston University Chobanian & Avedisian School of Medicine and Atrius Health. Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 

 

Physician AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of .50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Massachusetts Physicians Opioid Education/Pain Management
.50 hour of Mass Opioid/Pain Management Education 

Nursing Accreditation
Contact Hours: .50, all of which is eligible for pharmacology credit

Physician Assistant Accreditation
Boston University Chobanian & Avedisian School of Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for .50 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



Interprofessional Continuing Education Credit
This activity was planned by and for the healthcare team, and learners will receive .50 Interprofessional Continuing Education (IPCE) credits for learning and change.

Available Credit

  • 0.50 AAPA Category I CME
  • 0.50 AMA PRA Category 1 Credit™

    Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • 0.50 MA Opioid Education Statement
  • 0.50 ANCC
    • 0.50 ANCC Pharmacology
  • 0.50 Participation
Please login or register to take this course.